Cargando…
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341169/ https://www.ncbi.nlm.nih.gov/pubmed/35926815 http://dx.doi.org/10.1016/j.annonc.2022.07.012 |
| _version_ | 1784760555080253440 |
|---|---|
| author | Lasagna, A. Bergami, F. Lilleri, D. Percivalle, E. Quaccini, M. Comolli, G. Sarasini, A. Sammartino, J.C. Ferrari, A. Arena, F. Cicognini, D. Schiavo, R. Lo Cascio, G. Baldanti, F. Pedrazzoli, P. Cassaniti, I. |
| author_facet | Lasagna, A. Bergami, F. Lilleri, D. Percivalle, E. Quaccini, M. Comolli, G. Sarasini, A. Sammartino, J.C. Ferrari, A. Arena, F. Cicognini, D. Schiavo, R. Lo Cascio, G. Baldanti, F. Pedrazzoli, P. Cassaniti, I. |
| author_sort | Lasagna, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9341169 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93411692022-08-01 Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment Lasagna, A. Bergami, F. Lilleri, D. Percivalle, E. Quaccini, M. Comolli, G. Sarasini, A. Sammartino, J.C. Ferrari, A. Arena, F. Cicognini, D. Schiavo, R. Lo Cascio, G. Baldanti, F. Pedrazzoli, P. Cassaniti, I. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2022-11 2022-08-01 /pmc/articles/PMC9341169/ /pubmed/35926815 http://dx.doi.org/10.1016/j.annonc.2022.07.012 Text en © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Lasagna, A. Bergami, F. Lilleri, D. Percivalle, E. Quaccini, M. Comolli, G. Sarasini, A. Sammartino, J.C. Ferrari, A. Arena, F. Cicognini, D. Schiavo, R. Lo Cascio, G. Baldanti, F. Pedrazzoli, P. Cassaniti, I. Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment |
| title | Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment |
| title_full | Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment |
| title_fullStr | Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment |
| title_full_unstemmed | Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment |
| title_short | Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment |
| title_sort | humoral and cellular response before and after the fourth bnt162b2 vaccine dose in patients with solid tumors on active treatment |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341169/ https://www.ncbi.nlm.nih.gov/pubmed/35926815 http://dx.doi.org/10.1016/j.annonc.2022.07.012 |
| work_keys_str_mv | AT lasagnaa humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT bergamif humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT lillerid humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT percivallee humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT quaccinim humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT comollig humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT sarasinia humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT sammartinojc humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT ferraria humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT arenaf humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT cicogninid humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT schiavor humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT locasciog humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT baldantif humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT pedrazzolip humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment AT cassanitii humoralandcellularresponsebeforeandafterthefourthbnt162b2vaccinedoseinpatientswithsolidtumorsonactivetreatment |